Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes

Gene Therapy

Volumn 10, Issue 5, 2003, Pages 367-374

  Grunebach F ^a   Muller M R ^a   Nencioni, A ^a   Brossart, P ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

CTL; Dendritic cells; Immunotherapy; RNA transfection

Indexed keywords

CD71 ANTIGEN; GREEN FLUORESCENT PROTEIN; LIPOSOME; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; RNA; TRANSFERRIN RECEPTOR;

ANTIGEN PRESENTING CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; GENE AMPLIFICATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA TRANSPORT; SENSITIVITY ANALYSIS; SIMULATION; T LYMPHOCYTE ACTIVATION; TECHNOLOGY;

CARCINOMA, RENAL CELL; DENDRITIC CELLS; GENE EXPRESSION; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; LUMINESCENT PROTEINS; LYMPHOCYTE ACTIVATION; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037344753     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301901     Document Type: Review

References (33)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
3. Bubenik J. Genetically engineered dendritic cell-based cancer vaccines. Int J Oncol 2001; 18: 475-478.
4. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29: 1247-1255.
5. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumour necrosis factor. J Exp Med 1994; 179: 1109-1118.
6. + dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.
7. Brossart P et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4238-4247.
8. Bakker AB et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995; 55: 5330-5334.
9. Brossart P et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732-736.
10. Seliger B et al. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2. 1-restricted cytotoxic T lymphocytes. Int J Cancer 2000; 87: 349-359.
11. Hsu FJ et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-58.
12. Brossart P, Bevan MJ. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997; 90: 1594-1599.
13. Specht JM et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213-1221.
14. Brossart P et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158: 3270-3276.
15. Kaplan JM et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999; 163: 699-707.
16. Condon C et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-1128.
17. Inaba K et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998; 188: 2163-2173.
18. Herr W et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96: 1857-1864.
19. Chang JW et al. Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies. Anticancer Res 2000; 20: 1329-1336.
20. Shaif-Muthana M et al. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 2000; 60: 6441-6447.
21. Scott-Taylor TH et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 2000; 1500: 265-279.
22. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472.
23. Nair SK et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16: 364-369.
24. Boczkowski D et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60: 1028-1034.
25. Nair SK et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235: 540-549.
26. Heiser A et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164: 5508-5514.
27. Heiser A et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001; 61: 3388-3393.
28. Van Tendeloo VF et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
29. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002; 80: 1-70.
30. Matz M et al. Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic Acids Res 1999; 27: 1558-1560.
31. Flechsler I et al. Comparison of antisense vectors and antisense oligonucleotides delivered by means of the new cationic lipids Unifectin and maxifectin. Adv Exp Med Biol 1998; 451: 469-472.
32. Surovoy A, Flechsler I, Jung GA. Novel series of serum-resistant lipoaminoacid compounds for cellular delivery of plasmid DNA. Adv Exp Med Biol 1998; 451: 461-467.
33. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30: 1-7.